2020
DOI: 10.13040/ijpsr.0975-8232.11(12).6149-56
|View full text |Cite
|
Sign up to set email alerts
|

Untitled

Abstract: Ropinirole hydrochloride, a non-ergoline dopamine agonist, administered orally for the treatment of Parkinson's disease and restless leg syndrome and belonged to BCS class III drug having high solubility and low permeability. The objective of the present research study was to enhance the permeability of ropinirole hydrochloride by selecting a suitable permeation enhancing agent from different classes of permeation enhancers. Received pure drug was authenticated by determining its melting point, solubility, sta… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 17 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?